Peripheral signalling involved in energy homeostasis control

Nutrition Research Reviews

Volumn 25, Issue 2, 2012, Pages 223-248

  Lancha, Andoni ^a,b   Frühbeck, Gema ^a,b   Gómez Ambrosi, Javier ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipokines; Cytokines; Energy homeostasis control; Hormones; Obesity; Peripheral signalling

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPONECTIN; AMYLIN; ANGIOTENSIN II; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; INTERLEUKIN 6; LACTOFERRIN; LEPTIN; MESSENGER RNA; MYOSTATIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOCALCIN; OSTEOPONTIN; PANCREAS POLYPEPTIDE; PEPTIDE YY [3-36]; RENIN; RESISTIN; SERINE PROTEINASE INHIBITOR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADIPOSE TISSUE; BODY WEIGHT; CONCENTRATION (PARAMETERS); DIET RESTRICTION; ENERGY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; INTESTINE; KIDNEY; LIPID STORAGE; LIVER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OBESITY; PANCREAS; POSTPRANDIAL STATE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; THYROID GLAND; WEIGHT;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CYTOKINES; DIGESTIVE SYSTEM; ENERGY INTAKE; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; OBESITY; PEPTIDE HORMONES; SEX HORMONE-BINDING GLOBULIN; SIGNAL TRANSDUCTION;

MUS;

EID: 84870435584     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422412000145     Document Type: Review

References (470)

1. Swinburn BA, Sacks G, Hall KD, et al. (2011) The global obesity pandemic: Shaped by global drivers and local environments. Lancet 378, 804-814.
2. Finucane MM, Stevens GA, Cowan MJ, et al. (2011) National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377, 557-567.
3. Kahn SE, Hull RL & Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840-846.
4. Van Gaal LF, Mertens IL & De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880.
5. Donath MY & Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11, 98-107.
6. Gregor MF & Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29, 415-445.
7. Calle EE (2007) Obesity and cancer. BMJ 335, 1107-1108.
8. Fabbrini E, Sullivan S & Klein S (2010) Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51, 679-689.
9. Pischon T, Boeing H, Hoffmann K, et al. (2008) General and abdominal adiposity and risk of death in Europe. N Engl J Med 359, 2105-2120.
10. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363, 2211-2219.
11. O'Rahilly S (2009) Human genetics illuminates the paths to metabolic disease. Nature 462, 307-314.
12. Woods SC (2009) The control of food intake: Behavioral versus molecular perspectives. Cell Metab 9, 489-498.
13. Fruhbeck G & Gómez-Ambrosi J (2003) Control of body weight: A physiologic and transgenic perspective. Diabetologia 46, 143-172.
14. Takahashi N, Li F, Hua K, et al. (2007) Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 6, 506-512.
15. Gómez-Ambrosi J, Rodríguez A, Catalán V, et al. (2008) The boneYadipose axis in obesity and weight loss. Obes Surg 18, 1134-1143.
16. Valentino MA, Lin JE, Snook AE, et al. (2011) A uroguanylinY GUC-2C endocrine axis regulates feeding in mice. J Clin Invest 121, 3578-3588.
17. Choi SJ, Yablonka-Reuveni Z, Kaiyala KJ, et al. (2011) Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice. Am J Physiol Endocrinol Metab 300, E1031-E1037.
18. Somogyi V, Gyorffy A, Scalise TJ, et al. (2011) Endocrine factors in the hypothalamic regulation of food intake in females: A review of the physiological roles and interactions of ghrelin, leptin, thyroid hormones, oestrogen and insulin. Nutr Res Rev 24, 132-154.
19. Field BC, Chaudhri OB & Bloom SR (2010) Bowels control brain: Gut hormones and obesity. Nat Rev Endocrinol 6, 444-453.
20. Kennedy GC (1953) The role of depot fat in the hypothalamic control of food intake in the rat. Proc Royal Soc London 140B, 579-592.
21. Fruhbeck G & Gómez Ambrosi J (2001) Rationale for the existence of additional adipostatic hormones. FASEB J 15, 1996-2006.
22. Fruhbeck G & Salvador J (2004) Role of adipocytokines in metabolism and disease. Nutr Res 24, 803-826.
23. Fruhbeck G, Gómez-Ambrosi J, Muruzábal FJ, et al. (2001) The adipocyte: A model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280, E827-E847.
24. Fruhbeck G & Go'mez-Ambrosi J (2005) Adipose tissue. In Encyclopedia of Human Nutrition, 2nd ed., pp. 1-14 [B Caballero, L Allen and A Prentice, editors]. Oxford, UK: Elsevier Ltd.
25. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. (2009) Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother 10, 239-254.
26. Zhang Y, Proenca R, Maffei M, et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432.
27. Morton GJ, Cummings DE, Baskin DG, et al. (2006) Central nervous system control of food intake and body weight. Nature 443, 289-295.
28. Myers MG Jr, Munzberg H, Leinninger GM, et al. (2009) The geometry of leptin action in the brain: More complicated than a simple ARC. Cell Metab 9, 117-123.
29. Tartaglia LA, Dembski M, Weng X, et al. (1995) Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-1271.
30. Lee GH, Proenca R, Montez JM, et al. (1996) Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632-635.
31. Fruhbeck G, Gómez-Ambrosi J & Martínez JA (1999) Preand postprandial expression of the leptin receptor splice variants OB-Ra and OB-Rb in murine peripheral tissues. Physiol Res 48, 189-195.
32. Fruhbeck G, Jebb SA & Prentice AM (1998) Leptin: Physiology and pathophysiology. Clin Physiol 18, 399-419.
33. Fruhbeck G & Salvador J (2000) Relations between leptin and the regulation of glucose metabolism. Diabetologia 43, 3-12.
34. Muruzábal FJ, Fruhbeck G, Gómez-Ambrosi J, et al. (2002) Immunocytochemical detection of leptin in nonmammalian vertebrate stomach. Gen Comp Endocrinol 128, 149-152.
35. Archanco M, Muruzábal FJ, Llopiz D, et al. (2003) Leptin expression in the rat ovary depends on estrous cycle. J Histochem Cytochem 51, 1269-1277.
36. Myers MG, Cowley MA & Munzberg H (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70, 537-556.
37. Morton GJ & Schwartz MW (2011) Leptin and the central nervous system control of glucose metabolism. Physiol Rev 91, 389-411.
38. Gautron L & Elmquist JK (2011) Sixteen years and counting: An update on leptin in energy balance. J Clin Invest 121, 2087-2093.
39. Gómez-Ambrosi J & Fruhbeck G (2007) Unlocking the molecular basis of obesity. Future Lipidol 2, 577-581.
40. Fruhbeck G (2006) Intracellular signalling pathways activated by leptin. Biochem J 393, 7-20.
41. Lindstrom P (2007) The physiology of obeseY hyperglycemic mice [ob/ob mice]. Sci World J 7, 666-685.
42. Pelleymounter MA, Cullen MJ, Baker MB, et al. (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269, 540-543.
43. Halaas JL, Gajiwala KS, Maffei M, et al. (1995) Weightreducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546.
44. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, et al. (1997) Direct effects of leptin on brown and white adipose tissue. J Clin Invest 100, 2858-2864.
45. Fruhbeck G, Aguado M, Gómez-Ambrosi J, et al. (1998) Lipolytic effect of in vivo leptin administration on adipocytes of lean and ob/ob mice, but not db/db mice. Biochem Biophys Res Commun 250, 99-102.
46. Gallardo N, Bonzón-Kulichenko E, Fernández-Agulloó T, et al. (2007) Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology 148, 5604-5610.
47. Wang MY, Lee Y & Unger RH (1999) Novel form of lipolysis induced by leptin. J Biol Chem 274, 17541-17544.
48. Hwa JJ, Fawzi AB, Graziano MP, et al. (1997) Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am J Physiol 272, R1204-R1209.
49. Montague CT, Farooqi IS, Whitehead JP, et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903-908.
50. Strobel A, Issad T, Camoin L, et al. (1998) A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18, 213-215.
51. Farooqi IS, Jebb SA, Langmack G, et al. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341, 879-884.
52. Farooqi IS, Matarese G, Lord GM, et al. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110, 1093-1103.
53. Licinio J, Caglayan S, Ozata M, et al. (2004) Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 101, 4531-4536.
54. Paz-Filho G, Wong ML & Licinio J (2011) Ten years of leptin replacement therapy. Obes Rev 12, e315-e323.
55. Rosenbaum M, Goldsmith R, Bloomfield D, et al. (2005) Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 115, 3579-3586.
56. Galgani JE, Greenway FL, Caglayan S, et al. (2010) Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients. J Clin Endocrinol Metab 95, 851-855.
57. Kadowaki T & Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26, 439-451.
58. Trujillo ME & Scherer PE (2005) Adiponectin Y journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257, 167-175.
59. Kadowaki T, Yamauchi T, Kubota N, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116, 1784-1792.
60. Yamauchi T, Kamon J, Ito Y, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769.
61. Hug C, Wang J, Ahmad NS, et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 101, 10308-10313.
62. Arita Y, Kihara S, Ouchi N, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83.
63. Weyer C, Funahashi T, Tanaka S, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930-1935.
64. Yang WS, Lee WJ, Funahashi T, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86, 3815-3819.
65. Hotta K, Funahashi T, Arita Y, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20, 1595-1599.
66. Spranger J, Kroke A, Mohlig M, et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361, 226-228.
67. Ouchi N, Kihara S, Arita Y, et al. (1999) Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 100, 2473-2476.
68. Berg AH, Combs TP, Du X, et al. (2001) The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 7, 947-953.
69. Combs TP, Wagner JA, Berger J, et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARg agonists: A potential mechanism of insulin sensitization. Endocrinology 143, 998-1007.
70. Matsuzawa Y, Funahashi T, Kihara S, et al. (2004) Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24, 29-33.
71. Maeda N, Shimomura I, Kishida K, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8, 731-737.
72. Kubota N, Terauchi Y, Yamauchi T, et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277, 25863-25866.
73. Yamauchi T, Nio Y, Maki T, et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13, 332-339.
74. Dridi S & Taouis M (2009) Adiponectin and energy homeostasis: Consensus and controversy. J Nutr Biochem 20, 831-839.
75. Qi Y, Takahashi N, Hileman SM, et al. (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10, 524-529.
76. Park S, Kim DS, Kwon DY, et al. (2011) Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol 23, 687-698.
77. Kubota N, Yano W, Kubota T, et al. (2007) Adiponectin stimulates AMP-Activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6, 55-68.
78. Fruhbeck G, Alonso R, Marzo F, et al. (1995) A modified method for the indirect quantitative analysis of phytate in foodstuffs. Anal Biochem 225, 206-212.
79. Steppan CM, Bailey ST, Bhat S, et al. (2001) The hormone resistin links obesity to diabetes. Nature 409, 307-312.
80. McTernan PG, Kusminski CM & Kumar S (2006) Resistin. Curr Opin Lipidol 17, 170-175.
81. Gómez-Ambrosi J & Fruhbeck G (2005) Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev 1, 227-234.
82. Rangwala SM, Rich AS, Rhoades B, et al. (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53, 1937-1941.
83. Satoh H, Nguyen MT, Miles PD, et al. (2004) Adenovirusmediated chronic 'hyper-resistinemia' leads to in vivo insulin resistance in normal rats. J Clin Invest 114, 224-231.
84. Qi Y, Nie Z, Lee Y-S, et al. (2006) Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55, 3083-3090.
85. Kusminski CM, McTernan PG & Kumar S (2005) Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci 109, 243-256.
86. Schwartz DR & Lazar MA (2011) Human resistin: Found in translation from mouse to man. Trends Endocrinol Metab 22, 259-265.
87. Azuma K, Katsukawa F, Oguchi S, et al. (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11, 997-1001.
88. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. (2003) Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88, 5452-5455.
89. Silha JV, Krsek M, Skrha JV, et al. (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur J Endocrinol 149, 331-335.
90. Lee JH, Chan JL, Yiannakouris N, et al. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88, 4848-4856.
91. Heilbronn LK, Rood J, Janderova L, et al. (2004) Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89, 1844-1848.
92. Fehmann HC & Heyn J (2002) Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 34, 671-673.
93. Chen MP, Chung FM, Chang DM, et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91, 295-299.
94. Heidemann C, Sun Q, van Dam RM, et al. (2008) Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 149, 307-316.
95. Utzschneider KM, Carr DB, Tong J, et al. (2005) Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48, 2330-2333.
96. Gómez-Ambrosi J & Fruhbeck G (2001) Do resistin and resistin-like molecules also link obesity to inflammatory diseases Ann Intern Med 135, 306-307.
97. Bokarewa M, Nagaev I, Dahlberg L, et al. (2005) Resistin, an adipokine with potent proinflammatory properties. J Immunol 174, 5789-5795.
98. Silswal N, Singh AK, Aruna B, et al. (2005) Human resistin stimulates the pro-inflammatory cytokines TNF-A and IL-12 in macrophages by NF-kB-dependent pathway. Biochem Biophys Res Commun 334, 1092-1101.
99. Kaser S, Kaser A, Sandhofer A, et al. (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309, 286-290.
100. Lehrke M, Reilly MP, Millington SC, et al. (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1, e45.
101. Reilly MP, Lehrke M, Wolfe ML, et al. (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111, 932-939.
102. Kusminski CM, da Silva NF, Creely SJ, et al. (2007) The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab 92, 270-276.
103. Tovar S, Nogueiras R, Tung LY, et al. (2005) Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol 153, R1-R5.
104. Park S, Hong SM, Sung SR, et al. (2008) Long-term effects of central leptin and resistin on body weight, insulin resistance, and b-cell function and mass by the modulation of hypothalamic leptin and insulin signaling. Endocrinology 149, 445-454.
105. Cifani C, Durocher Y, Pathak A, et al. (2009) Possible common central pathway for resistin and insulin in regulating food intake. Acta Physiol 196, 395-400.
106. Vázquez MJ, González CR, Varela L, et al. (2008) Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 149, 4534-4543.
107. Singhal NS, Lazar MA & Ahima RS (2007) Central resistin induces hepatic insulin resistance via neuropeptide Y. J Neurosci 27, 12924-12932.
108. Kim KH, Lee K, Moon YS, et al. (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276, 11252-11256.
109. Nogueiras R, Novelle MG, Vazquez MJ, et al. (2010) Resistin: Regulation of food intake, glucose homeostasis and lipid metabolism. Endocr Dev 17, 175-184.
110. Maslowska M, Sniderman AD, Germinario R, et al. (1997) ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Relat Metab Disord 21, 261-266.
111. Cianflone K, Xia Z & Chen LY (2003) Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609, 127-143.
112. Yasruel Z, Cianflone K, Sniderman AD, et al. (1991) Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids 26, 495-499.
113. Germinario R, Sniderman AD, Manuel S, et al. (1993) Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 42, 574-580.
114. Saleh J, Al-Wardy N, Farhan H, et al (2011) Acylation stimulating protein: A female lipogenic factor Obes Rev 12, 440-448.
115. Xia Z, Stanhope KL, Digitale E, et al. (2004) Acylation-stimulating protein (ASP)/complement C3adesArg deficiency results in increased energy expenditure in mice. J Biol Chem 279, 4051-4057.
116. Xia Z, Sniderman AD & Cianflone K (2002) Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J Biol Chem 277, 45874-45879.
117. Paglialunga S, Schrauwen P, Roy C, et al. (2007) Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol 194, 293-304.
118. Paglialunga S, Fisette A, Munkonda M, et al. (2010) The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype mice. BMC Physiol 10, 4.
119. Roy C, Roy MC, Gauvreau D, et al. (2011) Acute injection of ASP in the third ventricle inhibits food intake and locomotor activity in rats. Am J Physiol Endocrinol Metab 301, E232-E241.
120. Rodríguez A, Catalán V, Gómez-Ambrosi J, et al. (2007) Visceral and subcutaneous adiposity: Are both potential therapeutic targets for tackling the metabolic syndrome Curr Pharm Des 13, 2169-2175.
121. Cawthorn WP, Heyd F, Hegyi K, et al. (2007) Tumour necrosis factor-A inhibits adipogenesis via a b-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 14, 1361-1373.
122. Cawthorn WP & Sethi JK (2008) TNF-A and adipocyte biology. FEBS Lett 582, 117-131.
123. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444, 860-867.
124. Uysal KT, Wiesbrock SM, Marino MW, et al. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-A function. Nature 389, 610-614.
125. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89, 381-410.
126. de Kloet AD, Pacheco-Lopez G, Langhans W, et al. (2011) The effect of TNFa on food intake and central insulin sensitivity in rats. Physiol Behav 103, 17-20.
127. Amaral ME, Barbuio R, Milanski M, et al. (2006) Tumor necrosis factor-A activates signal transduction in hypothalamus and modulates the expression of pro-inflammatory proteins and orexigenic/anorexigenic neurotransmitters. J Neurochem 98, 203-212.
128. Fruhbeck G, Sesma P & Burrell MA (2009) PRDM16: The interconvertible adipo-myocyte switch. Trends Cell Biol 19, 141-146.
129. Fruhbeck G, Becerril S, Sáinz N, et al. (2009) BAT: A new target for human obesity Trends Pharmacol Sci 30, 387-396.
130. Cypess AM, Lehman S, Williams G, et al. (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360, 1509-1517.
131. Masaki T, Yoshimatsu H, Chiba S, et al. (1999) Tumor necrosis factor-A regulates in vivo expression of the rat UCP family differentially. Biochim Biophys Acta 1436, 585-592.
132. Valladares A, Roncero C, Benito M, et al. (2001) TNF-A inhibits UCP-1 expression in brown adipocytes via ERKs. Opposite effect of p38MAPK. FEBS Lett 493, 6-11.
133. Romanatto T, Roman EA, Arruda AP, et al. (2009) Deletion of tumor necrosis factor-A receptor 1 (TNFR1) protects against diet-induced obesity by means of increased thermogenesis. J Biol Chem 284, 36213-36222.
134. Bastard JP, Maachi M, Van Nhieu JT, et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87, 2084-2089.
135. Tilg H & Moschen AR (2008) Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14, 222-231.
136. Wallenius V, Wallenius K, Ahren B, et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8, 75-79.
137. Carey AL, Steinberg GR, Macaulay SL, et al. (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-Activated protein kinase. Diabetes 55, 2688-2697.
138. Wallenius K, Wallenius V, Sunter D, et al. (2002) Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293, 560-565.
139. Chida D, Osaka T, Hashimoto O, et al. (2006) Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes 55, 971-977.
140. Benrick A, Schele E, Pinnock SB, et al. (2009) Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei. J Neuroendocrinol 21, 620-628.
141. Stouthard JM, Romijn JA, Van der Poll T, et al. (1995) Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 268, E813-E819.
142. Tsigos C, Papanicolaou DA, Defensor R, et al. (1997) Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66, 54-62.
143. Kubaszek A, Pihlajamaki J, Punnonen K, et al. (2003) The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52, 558-561.
144. Hoene M & Weigert C (2008) The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev 9, 20-29.
145. Ouchi N, Parker JL, Lugus JJ, et al. (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11, 85-97.
146. Fukuhara A, Matsuda M, Nishizawa M, et al. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426-430.
147. Fukuhara A, Matsuda M, Nishizawa M, et al. (2007) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin: Retraction. Science 318, 565.
148. Berndt J, Kloting N, Kralisch S, et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54, 2911-2916.
149. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. (2011) Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 21, 245-253.
150. Revollo JR, Korner A, Mills KF, et al. (2007) Nampt/PBEF/visfatin regulates insulin secretion in b cells as a systemic NAD biosynthetic enzyme. Cell Metab 6, 363-375.
151. Moschen AR, Kaser A, Enrich B, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178, 1748-1758.
152. Park BS, Jin SH, Park JJ, et al. (2011) Visfatin induces sickness responses in the brain. PLoS ONE 6, e15981.
153. Arner P (2006) Editorial: Visfatin Y a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 91, 28-30.
154. Hida K, Wada J, Eguchi J, et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: A unique insulinsensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 102, 10610-10615.
155. Kloting N, Berndt J, Kralisch S, et al. (2006) Vaspin gene expression in human adipose tissue: Association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339, 430-436.
156. Youn BS, Kloting N, Kratzsch J, et al. (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57, 372-377.
157. Zvonic S, Lefevre M, Kilroy G, et al. (2007) Secretome of primary cultures of human adipose-derived stem cells: Modulation of serpins by adipogenesis. Mol Cell Proteomics 6, 18-28.
158. González CR, Caminos JE, Vázquez MJ, et al. (2009) Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol 587, 3741-3750.
159. Jeong E, Youn BS, Kim DW, et al. (2010) Circadian rhythm of serum vaspin in healthy male volunteers: Relation to meals. J Clin Endocrinol Metab 95, 1869-1875.
160. Kloting N, Kovacs P, Kern M, et al. (2011) Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 54, 1819-1823.
161. Brunetti L, Di Nisio C, Recinella L, et al. (2011) Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 32, 1866-1871.
162. Ernst MC & Sinal CJ (2010) Chemerin: At the crossroads of inflammation and obesity. Trends Endocrinol Metab 21, 660-667.
163. Bozaoglu K, Bolton K, McMillan J, et al. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148, 4687-4694.
164. Goralski KB, McCarthy TC, Hanniman EA, et al. (2007) Chemerin: A novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 282, 28175-28188.
165. Hart R & Greaves DR (2010) Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol 185, 3728-3739.
166. Sell H, Divoux A, Poitou C, et al. (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 95, 2892-2896.
167. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. (2011) Increased levels of chemerin and its receptor, chemokinelike receptor-1, in obesity are related to inflammation: Tumor necrosis factor-A stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis (epublication ahead of print version 10 November 2011).
168. Schaffler A, Neumeier M, Herfarth H, et al. (2005) Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732, 96-102.
169. Yang RZ, Lee MJ, Hu H, et al. (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290, E1253-E1261.
170. de Souza Batista CM, Yang RZ, Lee MJ, et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56, 1655-1661.
171. Tan BK, Adya R & Randeva HS (2010) Omentin: A novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 20, 143-148.
172. Moreno-Navarrete JM, Catala'n V, Ortega F, et al. (2010) Circulating omentin concentration increases after weight loss. Nutr Metab 7, 27.
173. Yvan-Charvet L & Quignard-Boulange A (2011) Role of adipose tissue reninYangiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 79, 162-168.
174. Kalupahana NS & Moustaid-Moussa N (2012) The reninY angiotensin system: A link between obesity, inflammation and insulin resistance. Obes Rev 13, 136-149.
175. Katovich MJ & Pachori A (2000) Effects of inhibition of the reninYangiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab 2, 3-14.
176. Luther JM & Brown NJ (2011) The reninYangiotensinY aldosterone system and glucose homeostasis. Trends Pharmacol Sci 32, 734-739.
177. Engeli S, Schling P, Gorzelniak K, et al. (2003) The adipose-tissue reninYangiotensinYaldosterone system: Role in the metabolic syndrome Int J Biochem Cell Biol 35, 807-825.
178. Massiera F, Seydoux J, Geloen A, et al. (2001) Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 142, 5220-5225.
179. Kouyama R, Suganami T, Nishida J, et al. (2005) Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146, 3481-3489.
180. Yvan-Charvet L, Even P, Bloch-Faure M, et al. (2005) Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54, 991-999.
181. Jayasooriya AP, Mathai ML, Walker LL, et al. (2008) Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci U S A 105, 6531-6536.
182. Brink M, Wellen J & Delafontaine P (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 97, 2509-2516.
183. Cassis L, Helton M, English V, et al. (2002) Angiotensin II regulates oxygen consumption. Am J Physiol Regul Integr Comp Physiol 282, R445-R453.
184. de Kloet AD, Krause EG, Kim DH, et al. (2009) The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology 150, 4114-4123.
185. Porter JP & Potratz KR (2004) Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats. Am J Physiol Regul Integr Comp Physiol 287, R422-R428.
186. de Kloet AD, Krause EG, Scott KA, et al. (2011) Central angiotensin II has catabolic action at white and brownadipose tissue. Am J Physiol Endocrinol Metab 301, E1081-E1091.
187. de Kloet AD, Krause EG & Woods SC (2010) The renin angiotensin system and the metabolic syndrome. Physiol Behav 100, 525-534.
188. Tchernof A & Despres JP (2000) Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 32, 526-536.
189. Mayes JS & Watson GH (2004) Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 5, 197-216.
190. Brown LM, Gent L, Davis K, et al. (2010) Metabolic impact of sex hormones on obesity. Brain Res 1350, 77-85.
191. Mauvais-Jarvis F (2011) Estrogen and androgen receptors: Regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab 22, 24-33.
192. Mattiasson I, Rendell M, Tornquist C, et al. (2002) Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res 34, 583-588.
193. Tsai EC, Boyko EJ, Leonetti DL, et al. (2000) Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 24, 485-491.
194. Kupelian V, Page ST, Araujo AB, et al. (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91, 843-850.
195. Marin P, Holmang S, Jonsson L, et al. (1992) The effects of testosterone treatment on body composition and metabolism in middle-Aged obese men. Int J Obes Relat Metab Disord 16, 991-997.
196. Eckel LA (2011) The ovarian hormone estradiol plays a crucial role in the control of food intake in females. Physiol Behav 104, 517-524.
197. Heine PA, Taylor JA, Iwamoto GA, et al. (2000) Increased adipose tissue in male and female estrogen receptor-A knockout mice. Proc Natl Acad Sci U S A 97, 12729-12734.
198. Musatov S, Chen W, Pfaff DW, et al. (2007) Silencing of estrogen receptor a in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc Natl Acad Sci U S A 104, 2501-2506.
199. Ropero AB, Alonso-Magdalena P, Quesada I, et al. (2008) The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids 73, 874-879.
200. Fan W, Yanase T, Nomura M, et al. (2005) Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54, 1000-1008.
201. Xu Y, Nedungadi TP, Zhu L, et al. (2011) Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab 14, 453-465.
202. Plum L, Belgardt BF & Bruning JC (2006) Central insulin action in energy and glucose homeostasis. J Clin Invest 116, 1761-1766.
203. Woods SC, Lotter EC, McKay LD, et al. (1979) Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282, 503-505.
204. Bruning JC, Gautam D, Burks DJ, et al. (2000) Role of brain insulin receptor in control of body weight and reproduction. Science 289, 2122-2125.
205. Schwartz MW, Woods SC, Porte D Jr, et al. (2000) Central nervous system control of food intake. Nature 404, 661-671.
206. Konner AC, Klockener T & Bruning JC (2009) Control of energy homeostasis by insulin and leptin: Targeting the arcuate nucleus and beyond. Physiol Behav 97, 632-638.
207. Rothwell NJ & Stock MJ (1988) Insulin and thermogenesis. Int J Obes 12, 98-103.
208. Menéndez JA & Atrens DM (1989) Insulin increases energy expenditure and respiratory quotient in the rat. Pharmacol Biochem Behav 34, 765-768.
209. Dulloo AG & Girardier L (1989) Energy expenditure and diet-induced thermogenesis in presence and absence of hyperphagia induced by insulin. Am J Physiol 257, R717-R725.
210. Jiang G & Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284, E671-E678.
211. Go'mez-Ambrosi J, Catalan V & Fruhbeck G (2009) The adipoYhepatoYinsular axis in glucose homeostasis. In Peptides in Energy Balance and Obesity, pp. 163-193 [G Fruhbeck, editor]. Wallingford: CABI Publishing.
212. Kalkhoff RK, Gossain VV & Matute ML (1973) Plasma glucagon in obesity. Response to arginine, glucose and protein administration. N Engl J Med 289, 465-467.
213. Starke AA, Erhardt G, Berger M, et al. (1984) Elevated pancreatic glucagon in obesity. Diabetes 33, 277-280.
214. Koeslag JH, Saunders PT & Terblanche E (2003) A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitusYsyndrome X complex. J Physiol 549, 333-346.
215. Penick SB & Hinkle LE Jr (1961) Depression of food intake induced in healthy subjects by glucagon. N Engl J Med 264, 893-897.
216. Geary N, Langhans W & Scharrer E (1981) Metabolic concomitants of glucagon-induced suppression of feeding in the rat. Am J Physiol 241, R330-R335.
217. Habegger KM, Heppner KM, Geary N, et al. (2010) The metabolic actions of glucagon revisited. Nat Rev Endocrinol 6, 689-697.
218. Schulman JL, Carleton JL, Whitney G, et al. (1957) Effect of glucagon on food intake and body weight in man. J Appl Physiol 11, 419-421.
219. Billington CJ, Briggs JE, Link JG, et al. (1991) Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am J Physiol 261, R501-R507.
220. Davidson IW, Salter JM & Best CH (1957) Calorigenic action of glucagon. Nature 180, 1124.
221. Gelling RW, Du XQ, Dichmann DS, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic a cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100, 1438-1443.
222. Lou PH, Gustavsson N, Wang Y, et al. (2011) Increased lipolysis and energy expenditure in a mouse model with severely impaired glucagon secretion. PLoS ONE 6, e26671.
223. Vuguin PM & Charron MJ (2011) Novel insight into glucagon receptor action: Lessons from knockout and transgenic mouse models. Diabetes Obes Metab 13, Suppl. 1, 144-150.
224. Schwartz TW, Holst JJ, Fahrenkrug J, et al. (1978) Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 61, 781-789.
225. Jorde R & Burhol PG (1984) Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity. Int J Obes 8, 393-397.
226. Pieramico O, Malfertheiner P, Nelson DK, et al. (1990) Interdigestive cycling and post-prandial release of pancreatic polypeptide in severe obesity. Int J Obes 14, 1005-1011.
227. Lassmann V, Vague P, Vialettes B, et al. (1980) Low plasma levels of pancreatic polypeptide in obesity. Diabetes 29, 428-430.
228. Holst JJ, Schwartz TW, Lovgreen NA, et al. (1983) Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 7, 529-538.
229. Asakawa A, Inui A, Yuzuriha H, et al. (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124, 1325-1336.
230. Ueno N, Inui A, Iwamoto M, et al. (1999) Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117, 1427-1432.
231. Batterham RL, Le Roux CW, Cohen MA, et al. (2003) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88, 3989-3992.
232. Schmidt PT, Naslund E, Gryback P, et al. (2005) A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 90, 5241-5246.
233. Cooper GJ, Willis AC, Clark A, et al. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84, 8628-8632.
234. Cummings DE & Overduin J (2007) Gastrointestinal regulation of food intake. J Clin Invest 117, 13-23.
235. Lutz TA (2010) The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol 298, R1475-R1484.
236. Boyle CN & Lutz TA (2011) Amylinergic control of food intake in lean and obese rodents. Physiol Behav 105, 129-137.
237. Trevaskis JL, Parkes DG & Roth JD (2010) Insights into amylinYleptin synergy. Trends Endocrinol Metab 21, 473-479.
238. Aronne L, Fujioka K, Aroda V, et al. (2007) Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92, 2977-2983.
239. Roth JD, Roland BL, Cole RL, et al. (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 105, 7257-7562.
240. Roth JD, Hughes H, Kendall E, et al. (2006) Antiobesity effects of the b-cell hormone amylin in diet-induced obese rats: Effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147, 5855-5864.
241. Mack C, Wilson J, Athanacio J, et al. (2007) Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 293, R1855-R1863.
242. Osaka T, Tsukamoto A, Koyama Y, et al. (2008) Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 29, 1028-1035.
243. Rushing PA, Hagan MM, Seeley RJ, et al. (2000) Amylin: A novel action in the brain to reduce body weight. Endocrinology 141, 850-853.
244. Murphy KG, Dhillo WS & Bloom SR (2006) Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 27, 719-727.
245. Badman MK & Flier JS (2005) The gut and energy balance: Visceral allies in the obesity wars. Science 307, 1909-1914.
246. Kojima M & Kangawa K (2005) Ghrelin: Structure and function. Physiol Rev 85, 495-522.
247. Murphy KG & Bloom SR (2006) Gut hormones and the regulation of energy homeostasis. Nature 444, 854-859.
248. Wren AM & Bloom SR (2007) Gut hormones and appetite control. Gastroenterology 132, 2116-2130.
249. Kojima M, Hosoda H, Date Y, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660.
250. Nakazato M, Murakami N, Date Y, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409, 194-198.
251. Tschop M, Smiley DL & Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407, 908-913.
252. Asakawa A, Inui A, Kaga T, et al. (2001) Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120, 337-345.
253. Wren AM, Seal LJ, Cohen MA, et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.
254. Rodríguez A, Gómez-Ambrosi J, Catalán V, et al. (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes 33, 541-552.
255. Cummings DE, Purnell JQ, Frayo RS, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714-1749.
256. Tschop M, Weyer C, Tataranni PA, et al. (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707-709.
257. Cummings DE, Weigle DS, Frayo RS, et al. (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346, 1623-1630.
258. Fruhbeck G, Diez Caballero A & Gil MJ (2004) Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 350, 308-309.
259. Fruhbeck G, Diez-Caballero A, Gil MJ, et al. (2004) The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 14, 606-612.
260. Holdstock C, Engstrom BE, O hrvall M, et al. (2003) Ghrelin and adipose tissue regulatory peptides: Effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 88, 3177-3183.
261. Wren AM, Small CJ, Abbott CR, et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540-2547.
262. Chen HY, Trumbauer ME, Chen AS, et al. (2004) Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and Agouti-related protein. Endocrinology 145, 2607-2612.
263. López M, Lage R, Saha AK, et al. (2008) Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 7, 389-399.
264. Wortley KE, Del Rincon JP, Murray JD, et al. (2005) Absence of ghrelin protects against early-onset obesity. J Clin Invest 115, 3573-3578.
265. Zigman JM, Nakano Y, Coppari R, et al. (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115, 3564-3572.
266. Pfluger PT, Kirchner H, Gunnel S, et al. (2008) Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol 294, G610-G618.
267. Nagaya N, Moriya J, Yasumura Y, et al. (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674-3679.
268. Nagaya N, Itoh T, Murakami S, et al. (2005) Treatment of cachexia with ghrelin in patients with COPD. Chest 128, 1187-1193.
269. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3, 153-165.
270. Brown JC (1971) A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can J Biochem 49, 255-261.
271. Song DH & Wolfe MM (2007) Glucose-dependent insulinotropic polypeptide and its role in obesity. Curr Opin Endocrinol Diabetes Obes 14, 46-51.
272. Roust LR, Stesin M, Go VL, et al. (1988) Role of gastric inhibitory polypeptide in postprandial hyperinsulinemia of obesity. Am J Physiol 254, E767-E774.
273. Drucker DJ (2007) The role of gut hormones in glucose homeostasis. J Clin Invest 117, 24-32.
274. Wideman RD & Kieffer TJ (2009) Mining incretin hormone pathways for novel therapies. Trends Endocrinol Metab 20, 280-286.
275. Fehmann HC, Goke R & Goke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16, 390-410.
276. Wasada T, McCorkle K, Harris V, et al. (1981) Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 68, 1106-1107.
277. Song DH, Getty-Kaushik L, Tseng E, et al. (2007) Glucosedependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 133, 1796-1805.
278. Althage MC, Ford EL, Wang S, et al. (2008) Targeted ablation of glucose-dependent insulinotropic polypeptideproducing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 283, 18365-18376.
279. Miyawaki K, Yamada Y, Ban N, et al. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8, 738-742.
280. Gault VA, Irwin N, Green BD, et al. (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54, 2436-2446.
281. Hansotia T, Maida A, Flock G, et al. (2007) Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117, 143-152.
282. Daousi C, Wilding JP, Aditya S, et al. (2009) Effects of peripheral administration of synthetic human glucosedependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol 71, 195-201.
283. Irwin N & Flatt PR (2009) Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 52, 1724-1731.
284. Baggio LL & Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157.
285. Kieffer TJ & Habener JF (1999) The glucagon-like peptides. Endocr Rev 20, 876-913.
286. Drucker DJ (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocr Metab 1, 22-31.
287. Nauck MA, Vardarli I, Deacon CF, et al (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down Diabetologia 54, 10-18.
288. Ranganath LR, Beety JM, Morgan LM, et al. (1996) Attenuated GLP-1 secretion in obesity: Cause or consequence Gut 38, 916-919.
289. Naslund E, Gryback P, Backman L, et al. (1998) Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43, 945-952.
290. Torekov SS, Madsbad S & Holst JJ (2011) Obesity Y an indication for GLP-1 treatment Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 12, 593-601.
291. Verdich C, Toubro S, Buemann B, et al. (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety Y effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25, 1206-1214.
292. Morínigo R, Moize V, Musri M, et al. (2006) Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91, 1735-1740.
293. Turton MD, O'Shea D, Gunn I, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
294. Flint A, Raben A, Astrup A, et al. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101, 515-520.
295. Gutzwiller JP, Goke B, Drewe J, et al. (1999) Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 44, 81-86.
296. Naslund E, Barkeling B, King N, et al. (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23, 304-311.
297. Flint A, Raben A, Ersboll AK, et al. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25, 781-792.
298. Williams DL, Baskin DG & Schwartz MW (2009) Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150, 1680-1687.
299. Osaka T, Endo M, Yamakawa M, et al. (2005) Energy expenditure by intravenous administration of glucagonlike peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26, 1623-1631.
300. Pannacciulli N, Bunt JC, Koska J, et al. (2006) Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 84, 556-560.
301. Knauf C, Cani PD, Ait-Belgnaoui A, et al. (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149, 4768-4777.
302. Ayala JE, Bracy DP, James FD, et al. (2010) Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151, 4678-4687.
303. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, et al. (2009) Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 29, 5916-5925.
304. Barrera JG, Jones KR, Herman JP, et al. (2011) Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31, 3904-3913.
305. Hayes MR, De Jonghe BC & Kanoski SE (2010) Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 100, 503-510.
306. Vilsboll T, Zdravkovic M, Le-Thi T, et al. (2007) Liraglutide, a long-Acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30, 1608-1610.
307. Astrup A, Rossner S, Van Gaal L, et al. (2009) Effects of liraglutide in the treatment of obesity: A randomised, doubleblind, placebo-controlled study. Lancet 374, 1606-1616.
308. Day JW, Ottaway N, Patterson JT, et al. (2009) A new glucagon and GLP-1 co-Agonist eliminates obesity in rodents. Nat Chem Biol 5, 749-757.
309. Tang Christensen M, Larsen PJ, Thulesen J, et al. (2000) The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6, 802-807.
310. Bahrami J, Longuet C, Baggio LL, et al. (2010) Glucagonlike peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 139, 857-868.
311. le Roux CW, Borg C, Wallis K, et al. (2010) Gut hypertrophy after gastric bypass is associated with increased glucagonlike peptide 2 and intestinal crypt cell proliferation. Ann Surg 252, 50-56.
312. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 30, 1335-1343.
313. Conarello SL, Li Z, Ronan J, et al. (2003) Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A 100, 6825-6830.
314. Tatemoto K & Mutt V (1980) Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285, 417-418.
315. Karra E & Batterham RL (2010) The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 316, 120-128.
316. Grandt D, Schimiczek M, Beglinger C, et al. (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: Characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51, 151-159.
317. Kirchner H, Tong J, Tschop MH, et al. (2010) Ghrelin and PYY in the regulation of energy balance and metabolism: Lessons from mouse mutants. Am J Physiol Endocrinol Metab 298, E909-E919.
318. Zac-Varghese S, De Silva A & Bloom SR (2011) Translational studies on PYY as a novel target in obesity. Curr Opin Pharmacol 11, 582-585.
319. Batterham RL, Cohen MA, Ellis SM, et al. (2003) Inhibition of food intake in obese subjects by peptide Y-3-36. N Engl J Med 349, 941-948.
320. Batterham RL, Cowley MA, Small CJ, et al. (2002) Gut hormone PY-3-36 physiologically inhibits food intake. Nature 418, 650-654.
321. Moran TH, Smedh U, Kinzig KP, et al. (2005) Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288, R384-R388.
322. Batterham RL, Ffytche DH, Rosenthal JM, et al. (2007) PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450, 106-109.
323. Tschop M, Castaneda TR, Joost HG, et al. (2004) Physiology: Does gut hormone PY-3-36 decrease food intake in rodents Nature 430, 1 p following 165; discussion 2 p following 165.
324. Schonhoff S, Baggio L, Ratineau C, et al. (2005) Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 25, 4189-4199.
325. Wortley KE, Garcia K, Okamoto H, et al. (2007) Peptide YY regulates bone turnover in rodents. Gastroenterology 133, 1534-1543.
326. Boey D, Lin S, Karl T, et al. (2006) Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49, 1360-1370.
327. Batterham RL, Heffron H, Kapoor S, et al. (2006) Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4, 223-233.
328. Sloth B, Holst JJ, Flint A, et al. (2007) Effects of PY-1-36 and PY-3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292, E1062-E1068.
329. Doucet E, Laviolette M, Imbeault P, et al. (2008) Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metabolism 57, 1458-1464.
330. Guo Y, Ma L, Enriori PJ, et al. (2006) Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity 14, 1562-1570.
331. Raybould HE (2007) Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol 7, 570-574.
332. Liddle RA, Goldfine ID, Rosen MS, et al. (1985) Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75, 1144-1152.
333. Lo CM, Samuelson LC, Chambers JB, et al. (2008) Characterization of mice lacking the gene for cholecystokinin. Am J Physiol Regul Integr Comp Physiol 294, R803-R810.
334. Crawley JN & Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15, 731-755.
335. Kopin AS, Mathes WF, McBride EW, et al. (1999) The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 103, 383-391.
336. Lo CM, King A, Samuelson LC, et al. (2010) Cholecystokinin knockout mice are resistant to high-fat diet-induced obesity. Gastroenterology 138, 1997-2005.
337. Gibbs J, Young RC & Smith GP (1973) Cholycystokinin elicits satiety in rats with open gastric fistulas. Nature 245, 323-325.
338. Smith GP, Jerome C, Cushin BJ, et al. (1981) Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213, 1036-1037.
339. Lieverse RJ, Jansen JB, Masclee AA, et al. (1995) Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36, 176-179.
340. Crawley JN & Beinfeld MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302, 703-706.
341. Jordan J, Greenway FL, Leiter LA, et al. (2008) Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83, 281-287.
342. Moran TH, Katz LF, Plata-Salaman CR, et al. (1998) Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 274, R618-R625.
343. Bataille D, Tatemoto K, Gespach C, et al. (1982) Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett 146, 79-86.
344. Le Quellec A, Kervran A, Blache P, et al. (1992) Oxyntomodulin-like immunoreactivity: Diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 74, 1405-1409.
345. Dubrasquet M, Bataille D & Gespach C (1982) Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): A potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 2, 391-395.
346. Schjoldager B, Mortensen PE, Myhre J, et al. (1989) Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 34, 1411-1419.
347. Schepp W, Dehne K, Riedel T, et al. (1996) Oxyntomodulin: A cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 57, 398-405.
348. Baggio LL, Huang Q, Brown TJ, et al. (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127, 546-558.
349. Parkinson JR, Chaudhri OB, Kuo YT, et al. (2009) Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 44, 1022-1031.
350. Dakin CL, Gunn I, Small CJ, et al. (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142, 4244-4250.
351. Dakin CL, Small CJ, Batterham RL, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145, 2687-2695.
352. Cohen MA, Ellis SM, Le Roux CW, et al. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88, 4696-4701.
353. Wynne K, Park AJ, Small CJ, et al. (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: A double-blind, randomized, controlled trial. Diabetes 54, 2390-2395.
354. Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283, E1173-E1177.
355. Wynne K & Bloom SR (2006) The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2, 612-620.
356. Potter LR (2011) Guanylyl cyclase structure, function and regulation. Cell Signal 23, 1921-1926.
357. Seeley RJ & Tschop MH (2011) Uroguanylin: How the gut got another satiety hormone. J Clin Invest 121, 3384-3386.
358. Carrithers SL, Ott CE, Hill MJ, et al. (2004) Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int 65, 40-53.
359. Fruhbeck G (2012) Gastrointestinal hormones: Uroguanylin Y a new gut-derived weapon against obesity Nat Rev Endocrinol 8, 5-6.
360. Lafontan M, Moro C, Berlan M, et al (2008) Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19, 130-137.
361. Beenken A & Mohammadi M (2009) The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8, 235-253.
362. Kir S, Beddow SA, Samuel VT, et al. (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624.
363. Tomlinson E, Fu L, John L, et al. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143, 1741-1747.
364. Fu L, John LM, Adams SH, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594-2603.
365. Wu X, Ge H, Lemon B, et al. (2010) Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A 107, 14158-14163.
366. Hirota K & Fukamizu A (2010) Transcriptional regulation of energy metabolism in the liver. J Recept Signal Transduct Res 30, 403-409.
367. Juul A (2003) Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13, 113-170.
368. Kawai M & Rosen CJ (2010) The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem 111, 14-19.
369. Baker J, Liu JP, Robertson EJ, et al. (1993) Role of insulinlike growth factors in embryonic and postnatal growth. Cell 75, 73-82.
370. Sandhu MS, Heald AH, Gibson JM, et al. (2002) Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet 359, 1740-1745.
371. Murphy LJ (2003) The role of the insulin-like growth factors and their binding proteins in glucose homeostasis. Experimental Diab Res 4, 213-224.
372. Clemmons DR (2006) Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 6, 620-625.
373. Saltiel AR & Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806.
374. Holzenberger M, Dupont J, Ducos B, et al. (2003) IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182-187.
375. Sanchez-Alavez M, Osborn O, Tabarean IV, et al. (2011) Insulin-like growth factor 1-mediated hyperthermia involves anterior hypothalamic insulin receptors. J Biol Chem 286, 14983-14990.
376. Frystyk J, Vestbo E, Skjaerbaek C, et al. (1995) Free insulinlike growth factors in human obesity. Metabolism 44, 37-44.
377. Le Marchand-Brustel Y, Heydrick SJ, Jullien D, et al. (1995) Effected of insulin and insulin-like growth factor-I on glucose transport and its transporters in soleus muscle of lean and obese mice. Metabolism 44, 18-23.
378. Vickers MH, Ikenasio BA & Breier BH (2001) IGF-I treatment reduces hyperphagia, obesity, and hypertension in metabolic disorders induced by fetal programming. Endocrinology 142, 3964-3973.
379. Foster LA, Ames NK & Emery RS (1991) Food intake and serum insulin responses to intraventricular infusions of insulin and IGF-I. Physiol Behav 50, 745-749.
380. Lauterio TJ, Marson L, Daughaday WH, et al. (1987) Evidence for the role of insulin-like growth factor II (IGF-II) in the control of food intake. Physiol Behav 40, 755-758.
381. Firth SM & Baxter RC (2002) Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 23, 824-854.
382. Wheatcroft SB, Kearney MT, Shah AM, et al. (2007) IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 56, 285-294.
383. Hedbacker K, Birsoy K, Wysocki RW, et al. (2010) Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 11, 11-22.
384. Kharitonenkov A & Larsen P (2011) FGF21 reloaded: Challenges of a rapidly growing field. Trends Endocrinol Metab 22, 81-86.
385. Tyynismaa H, Raivio T, Hakkarainen A, et al. (2011) Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 96, E351-E355.
386. Badman MK, Pissios P, Kennedy AR, et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5, 426-437.
387. Galman C, Lundasen T, Kharitonenkov A, et al. (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARa activation in man. Cell Metab 8, 169-174.
388. Kharitonenkov A, Shiyanova TL, Koester A, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115, 1627-1635.
389. Dushay J, Chui PC, Gopalakrishnan GS, et al. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139, 456-463.
390. Fisher FM, Chui PC, Antonellis PJ, et al. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789.
391. Xu J, Lloyd DJ, Hale C, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259.
392. Sarruf DA, Thaler JP, Morton GJ, et al. (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817-1824.
393. Hondares E, Iglesias R, Giralt A, et al. (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 286, 12983-12990.
394. Hammond GL (2011) Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 85, 431-441.
395. Svendsen OL, Hassager C & Christiansen C (1993) Impact of regional and total body composition and hormones on resting energy expenditure in overweight postmenopausal women. Metabolism 42, 1588-1591.
396. Abate N, Haffner SM, Garg A, et al. (2002) Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 87, 4522-4527.
397. Ding EL, Song Y, Manson JE, et al. (2009) Sex hormonebinding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361, 1152-1163.
398. Calle EE & Kaaks R (2004) Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4, 579-591.
399. Zurlo F, Larson K, Bogardus C, et al. (1990) Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 86, 1423-1427.
400. van den Berg SA, van Marken Lichtenbelt W, Willems van Dijk K, et al. (2011) Skeletal muscle mitochondrial uncoupling, adaptive thermogenesis and energy expenditure. Curr Opin Clin Nutr Metab Care 14, 243-249.
401. Bostrom P, Wu J, Jedrychowski MP, et al. (2012) A PGC1-A-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463-468.
402. Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20, 61-86.
403. Zimmers TA, Davies MV, Koniaris LG, et al. (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486-1488.
404. Rebbapragada A, Benchabane H, Wrana JL, et al. (2003) Myostatin signals through a transforming growth factor b-like signaling pathway to block adipogenesis. Mol Cell Biol 23, 7230-7242.
405. McPherron AC & Lee SJ (2002) Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 109, 595-601.
406. Zhang C, McFarlane C, Lokireddy S, et al. (2012) Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 55, 183-193.
407. Guo T, Jou W, Chanturiya T, et al. (2009) Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE 4, e4937.
408. Hittel DS, Berggren JR, Shearer J, et al. (2009) Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 58, 30-38.
409. Sa'inz N, Rodri'guez A, Catala'n V, et al. (2009) Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1a in ob/ob mice. PLoS ONE 4, e6808.
410. Brinkoetter M, Magkos F, Vamvini M, et al. (2011) Leptin treatment reduces body fat but does not affect lean body mass or the myostatinYfollistatinYactivin axis in lean hypoleptinemic women. Am J Physiol Endocrinol Metab 301, E99-E104.
411. Pan H, Ping XC, Zhu HJ, et al. (2012) Association of myostatin gene polymorphisms with obesity in Chinese north Han human subjects. Gene 494, 237-241.
412. Takahashi N, Lopez ML, Cowhig JE Jr, et al. (2005) Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are indistinguishable from wild-type. J Am Soc Nephrol 16, 125-132.
413. Szczepanska-Sadowska E, Paczwa P & Dobruch J (2003) Enhanced food and water intake in renin transgenic rats. J Physiol Pharmacol 54, 81-88.
414. Uehara S, Tsuchida M, Kanno T, et al. (2003) Late-onset obesity in mice transgenic for the human renin gene. Int J Mol Med 11, 723-727.
415. Gratze P, Boschmann M, Dechend R, et al. (2009) Energy metabolism in human renin-gene transgenic rats: Does renin contribute to obesity Hypertension 53, 516-523.
416. Kishimoto I, Tokudome T, Nakao K, et al. (2011) Natriuretic peptide system: An overview of studies using genetically engineered animal models. FEBS J 278, 1830-1841.
417. Beleigoli AM, Diniz MF & Ribeiro AL (2009) Natriuretic peptides: Linking heart and adipose tissue in obesity and related conditions Y a systematic review. Obes Rev 10, 617-626.
418. Pandey KN (2011) The functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: Perspectives and paradigms. FEBS J 278, 1792-1807.
419. Kuhn M (2003) Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93, 700-709.
420. Sarzani R, Dessi-Fulgheri P, Paci VM, et al. (1996) Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 19, 581-585.
421. Engeli S & Sharma AM (2001) The reninYangiotensin system and natriuretic peptides in obesity-Associated hypertension. J Mol Med 70, 21-29.
422. Gómez-Ambrosi J, Catalán V, Diez-Caballero A, et al. (2004) Gene expression profile of omental adipose tissue in human obesity. FASEB J 18, 215-217.
423. Moro C & Smith SR (2009) Natriuretic peptides: New players in energy homeostasis. Diabetes 58, 2726-2728.
424. Birkenfeld AL, Boschmann M, Moro C, et al. (2005) Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90, 3622-3628.
425. Sarzani R, Marcucci P, Salvi F, et al. (2008) Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes 32, 259-267.
426. Wang TJ, Larson MG, Levy D, et al. (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109, 594-600.
427. Inuzuka M, Tamura N, Yamada N, et al. (2010) C-type natriuretic peptide as a new regulator of food intake and energy expenditure. Endocrinology 151, 3633-3642.
428. Miyashita K, Itoh H, Tsujimoto H, et al. (2009) Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58, 2880-2892.
429. Birkenfeld AL, Budziarek P, Boschmann M, et al. (2008) Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 57, 3199-3204.
430. Kim B (2008) Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid 18, 141-144.
431. Baxter JD & Webb P (2009) Thyroid hormone mimetics: Potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8, 308-320.
432. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81, 1097-1142.
433. Zhang J & Lazar MA (2000) The mechanism of action of thyroid hormones. Annu Rev Physiol 62, 439-466.
434. Reinehr T (2010) Obesity and thyroid function. Mol Cell Endocrinol 316, 165-171.
435. Silva JE (2003) The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 139, 205-213.
436. Alkemade A (2010) Central and peripheral effects of thyroid hormone signalling in the control of energy metabolism. J Neuroendocrinol 22, 56-63.
437. Barros RP & Gustafsson JA (2011) Estrogen receptors and the metabolic network. Cell Metab 14, 289-299.
438. Park CJ, Zhao Z, Glidewell-Kenney C, et al. (2011) Genetic rescue of nonclassical ERa signaling normalizes energy balance in obese Era-null mutant mice. J Clin Invest 121, 604-612.
439. Foryst-Ludwig A, Clemenz M, Hohmann S, et al. (2008) Metabolic actions of estrogen receptor beta (ERb) are mediated by a negative cross-talk with PPARg. PLoS Genet 4, e1000108.
440. Dillo WS (2007) Appetite regulation: An overview. Thyroid 17, 433-445.
441. Ishii S, Kamegai J, Tamura H, et al. (2008) Triiodothyronine (T3) stimulates food intake via enhanced hypothalamic AMP-Activated kinase activity. Regul Pept 151, 164-169.
442. López M, Varela L, Vázquez MJ, et al. (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16, 1001-1008.
443. Kaptein EM, Beale E & Chan LS (2009) Thyroid hormone therapy for obesity and nonthyroidal illnesses: A systematic review. J Clin Endocrinol Metab 94, 3663-3675.
444. Zhao LJ, Liu YJ, Liu PY, et al. (2007) Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92, 1640-1646.
445. Galusca B, Zouch M, Germain N, et al. (2008) Constitutional thinness: Unusual human phenotype of low bone quality. J Clin Endocrinol Metab 93, 110-117.
446. Clemens TL & Karsenty G (2011) The osteoblast: An insulin target cell controlling glucose homeostasis. J Bone Miner Res 26, 677-680.
447. Scatena M, Liaw L & Giachelli CM (2007) Osteopontin. A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27, 2302-2309.
448. Reinholt FP, Hultenby K, Oldberg A, et al. (1990) Osteopontin Y a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 87, 4473-4475.
449. Gómez-Ambrosi J, Catalán V, Ramírez B, et al. (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92, 3719-3727.
450. Nomiyama T, Perez-Tilve D, Ogawa D, et al. (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117, 2877-2888.
451. Kiefer FW, Zeyda M, Todoric J, et al. (2008) Osteopontin expression in human and murine obesity: Extensive local upregulation in adipose tissue but minimal systemic alterations. Endocrinology 149, 1350-1357.
452. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. (2009) Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and -9 activity in humans. J Mol Med 87, 803-813.
453. Chapman J, Miles PD, Ofrecio JM, et al. (2010) Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS ONE 5, e13959.
454. Pietilainen KH, Naukkarinen J, Rissanen A, et al. (2008) Global transcript profiles of fat in monozygotic twins discordant for BMI: Pathways behind acquired obesity. PLoS Med 5, e51.
455. Hurtado Del Pozo C, Calvo RM, Vesperinas-Garcia G, et al. (2010) IPO8 and FBXL10: New reference genes for gene expression studies in human adipose tissue. Obesity 18, 897-903.
456. Kiefer FW, Zeyda M, Gollinger K, et al. (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59, 935-946.
457. Bertola A, Deveaux V, Bonnafous S, et al. (2009) Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 58, 125-133.
458. Syn WK, Choi SS, Liaskou E, et al. (2011) Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53, 106-115.
459. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. (2011) Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J Nutr Biochem 22, 634-641.
460. Calvo MS, Eyre DR & Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17, 333-368.
461. Kanazawa I, Yamaguchi T, Yamamoto M, et al. (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94, 45-49.
462. Fernández-Real JM & Ricart W (2011) Osteocalcin: A new link between bone and energy metabolism. Some evolutionary clues. Curr Opin Clin Nutr Metab Care 14, 360-366.
463. Ducy P (2011) The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia 54, 1291-1297.
464. Lee NK, Sowa H, Hinoi E, et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469.
465. Martin TJ (2007) A skeleton key to metabolism. Nat Med 13, 1021-1023.
466. Ferron M, Hinoi E, Karsenty G, et al. (2008) Osteocalcin differentially regulates b cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 105, 5266-5270.
467. Ferron M, McKee MD, Levine RL, et al. (2012) Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 50, 568-575.
468. Kanazawa I, Yamaguchi T, Tada Y, et al. (2011) Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 48, 720-725.
469. Fernández-Real JM, Izquierdo M, Ortega F, et al. (2009) The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 94, 237-245.
470. Yoshikawa Y, Kode A, Xu L, et al. (2011) Genetic evidence points to an osteocalcin-independent influence of osteoblasts on energy metabolism. J Bone Miner Res 26, 2012-2025.